

# INDEX

## A

Acrylamides, 118  
 Actin cytoskeleton, 17–18  
 Adenosine deaminase deficiency, 131  
 Adhesive peptide sequences within ECM proteins, 12  
 Adhesive peptides, 37  
 Adsorbed proteins, conformation of, 22  
 Aliphatic polyanhydrides, 177  
   copolymers, 182  
 Allografts, 47  
 Alpha, 1-glycoprotein (alpha 1-GP) 65  
 Alzheimer's disease, 64, 67, 210  
 Amine-modified surfaces, 29  
 Amyotrophic lateral sclerosis (ALS), 67  
 Angiogenesis inhibitors, 210  
 Angiogenic biomaterials, 3  
 Anhydride interchange mechanism, 175  
 Anti-adhesive matrix molecules, 17–18  
 Anti-PECAM, 120  
 Apoptosis, 23–24  
   adhesion-dependent control, 23  
 Appropriate host response, 3  
 Arg–Gly–Asp peptides (RGD), 11, 37–38, 63, 104  
 Asialoglycoprotein, 40  
 Astrocytes, 48  
 Atomic force microscopy (AFM), 195  
 ATR–FTIR spectroscopy, 111  
 Autografts, 47  
 Axonal growth  
   control of, 55  
   electrically mediated guidance, 60  
   longitudinally directed, 61  
 Azo-compounds, 121

## B

Baby hamster fibroblast cell line (BHK), 67–68  
 Basic fibroblast growth factor (b-FGF), 65  
 BCECF–am, 122

BCNU, 210  
 Bethanechol, 210  
 Bioactive agents, 2  
 Bioactive factor delivery, 159–160  
 Biocompatibility, 1–5  
   concept of, 3  
   host response central to, 5  
 Biodegradable conduits, comparative studies, 59  
 Biodegradable materials, 50  
 Biodegradable polymer scaffolds, 61  
 Bioerodible polymers, 169  
   functional groups found in, 171  
 Biohybrid nerve guide, 56  
 Biological response, 5  
 Biologically active materials vs. drugs, 4  
 Biomaterials  
   as agonists of biological response, 3  
   inert, 1–2  
   overview, 1–6  
   synthesis, 15  
   three-dimensional polymeric networks as, 76–105  
 Blood compatibility, 3  
 Bone and GAMs  
   larger animals, 160–161  
   small animals, 160  
   summary, 161  
 Bone morphogenetic proteins (BMPs), 159  
 Bone regeneration, 158–159  
 Bone tissue engineering, 159–161  
 Bovine serum albumin (BSA), 65  
 Bulk erosion, 172

## C

<sup>13</sup>C-NMR studies, 96  
 Carbohydrates, 13, 15  
 Carcinomas, 210  
 Cationic lipids, 136–138  
 Cationic polymers, 138–141  
 CD36, 17  
 CD44, 16–17

- CD44–ligand interaction, 16
- CD44 receptors, 16
- Cell adhesion, 7–8, 11, 21–25, 28–29, 32–33, 40
- Cell-adhesion ligands, 36–41
- Cell attachment to quaternary amine surfaces, 29
- Cell contractility, 25
- Cell-derived matrix, 21
- Cell differentiation, 21–23
- Cell encapsulation *see* Cell encapsulation
- Cell integrity, 28
- Cell–material interactions, 7–46
  - controlled, 33–41
  - nonspecific, 25–33
- Cell migration, 24–25
- Cell motility, 24–25
- Cell placement and growth, 55–56
- Cell-recognition processes, 14
- Cell–substrate contacts, 22
- Cell–substrate interactions, 8, 18–19, 24
- Cell–surface glycosaminoglycan, 29
- Cell surface receptors
  - activation, 13
  - and their ligands, 8–18
  - recognition, 34
- Cellular differentiation, 32
- Central nervous systems, polymers for
  - regeneration, 60–64
- Cetyltrimethylammonium bromide (CTAB), 153
- Charge transfer complexes, 92
- Charged surfaces, 28
  - cell response to, 29
- Chemical cues, 50–51
- Chemical potential change due to elastic retractive forces, 79
- Chemotherapeutic agents delivery using hydrogels, 121
- Chinese hamster ovary (CHO) cells, 28
- Chitosan, 112, 142, 153, 155
- Chitosan–DNA microspheres, 156
- Chitosan–DNA nanoparticles, 155
- Chitosan–DNA nanospheres, 155
- Chloroquine, 155
- Chondroitin sulfate, 29
- Chondroitinase ABC, 29
- Ciliary neurotrophic factor (CNTF), 67–68
- Collagen, 16, 20–21, 36, 50–51, 55, 57, 60
- Collagen GAMs, 161
- Collagen nerve guide, 56
- Collagen–NGF mixtures, 51
- Combinatorial chemistry, 75
- Complementary DNA, 122
- Complexation in polymers, 92–98
  - effect of PEG chain length, 92–96
  - interpolymer, 92–96
  - overview, 92
- Complexation of poly(ethylene glycols), 92
- Compound muscle action potential (CMAP), 59
- Compression molding, 201
- Concanavalin-A (Con-A), 118
- Conduit materials, comparative studies, 57–60
- Configurational biomimetic imprinted networks, 78
- Controlled cell–material interactions, 33–41
- Controlled delivery, polymers for, 141
- Controlled DNA delivery, polymeric scaffolds for, 157–162
- Controlled DNA release, polymer based particles for, 141–157
- Controlled release, polyanhydride carriers for, 209–213
- Controlled-release device, 86
- Controlled-release polymers, 64–66
- Corticospinal tract (CST), 60
- Covalently immobilized adhesive peptide sequences, 36–37
- Cystic fibrosis, 131
- Cytoplasmic alkalization, 19
- Cytoskeletal organization, 30

## D

- DDAB, 151–153
- Degradation, use of term, 170
- Degradation half-lives, 170
- Dehydrative coupling, 175–176
- Dehydrochlorination, 173, 175
- Dendrimers, 121
- Dextran, 139
- Dichloromethane (DCM), 191–192, 200
- Differential scanning calorimetry (DSC), 194
- Diffusion, fundamentals of, 84–87
- Diffusion coefficients, 85–86
- Diffusion equations, 83
- Dimethylformamide (DMF), 191

Directed growth methods, 52  
 DMAEMA, 114  
 DMSO, 192  
 DNA  
   degradation, 147  
   delivery, 136–137, 141  
   denaturation, 146  
   release from scaffolds, 161–162  
   release in vaccination applications,  
     153–157  
   sequences, 122  
   synthesis, 21  
   vaccinations, 142, 162  
   *see also* Plasmid DNA  
 DNA/DDAB complexes, 151  
 DNA–gelatin microspheres, 154  
 DOTAP, 153  
 Double-emulsion solvent-evaporation  
   technique, 146  
 Drug delivery, 2  
   surface-erodible biomaterials for,  
     169–218  
 Drug release  
   chemically-controlled, 84  
   control mechanisms, 170  
   diffusion-controlled, 84  
   swelling-controlled, 84  
 Drugs vs. biologically active materials, 4

## E

E–selectin, 15, 40  
 ECM, 9–10, 17, 104  
   coatings, 22  
   components, 16, 20, 24, 48–49, 104  
   environment, 20  
   geometry, 22  
   layers, 31  
   ligands, 19  
   molecules, 15–16, 22  
   orientation, 31–32  
   production, 33, 39  
   properties, 31  
   proteins, 11, 34, 36, 41  
     adhesive peptide sequences within, 12  
   synthesis, 39  
 ECM–integrin interactions, 21  
 EILDV, 37  
 Electrical cues, 51

Encapsulation, 66–68  
   advantages over injection, 143  
   plasmid DNA, 143–150, 152, 154  
 Endothelial cells, 21, 33, 104  
 Entubulization, 48  
   degradable polymers for, 52–57  
   nondegradable polymers for, 50–52  
 Equilibrium swelling theory, 79–81  
 Erosion  
   characterization, 170  
   use of term, 170  
 Ethyl cellulose, 113  
 Eucaryotic cells, 13  
 Eudragit 100 gels, 119  
 Extracellular matrix *see* ECM

## F

Fabrication methods for porous conduits,  
   56–57  
 Factor XII, 3  
 FAD, 178  
 FDA, 2  
 Fibrillar adhesions, 20  
 Fibroblast growth factor (FGF), 51  
 Fibroblasts, 20–21, 33, 50  
 Fibronectin, 16, 20, 22, 27, 36, 50, 55, 64  
 Fickian diffusion theory, 85  
 Fick's law of diffusion, 84  
 Flory–Rehner theory, 79–80  
 Fluorinated polyanhydrides, 189  
 Focal adhesions, 19, 25  
 Foreign body response, 101–102  
 FT-IR spectroscopy, 94

## G

Galactose, 15  
 Gelatin, 142, 153–154  
 Gene activated matrices (GAMs),  
   157–158  
   and bone  
     larger animals, 160–161  
     small animals, 160  
     summary, 161  
 Gene delivery  
   advantages, 133  
   methods, 133–136

Gene therapy, 131–168  
 and protein delivery, 132–133  
 concept of, 162  
*ex vivo*, 133  
*in vivo*, 133–134  
 nonviral, 136  
   biomaterials for, 136–141  
 overview, 131–132  
 viral, 135  
 Genetic immunization, 142–143  
 Gibbs free energy, 79  
 Glial cell line-derived neurotrophic factor (GDNF), 65  
 Glial growth factor (GGF), 53  
 Glioblastoma multiforma, polyanhydride discs for treatment of, 210  
 Glucose response following infusion of human insulin, 107  
 Glucose-sensitive systems, 117–119  
 Glycocalyx, 14, 29  
 Glycopeptides, 39  
 Glycoproteins, 14  
 Glycosaminoglycann (GAG), 15  
 GPC, 191  
 GRGDY, 37  
 Growth factor administration, 64

## H

<sup>1</sup>H-NMR spectroscopy, 96, 198  
 Hemocompatibility testing, 5  
 Hemophilia, 131–132  
 Heparin immobilization, 1  
 Hepatocytes, 39  
 Host response central to biocompatibility, 5  
 Human insulin concentration, 107  
 Human nerve growth factor gene (hNGF), 67  
 Huntington's disease, 68  
 Hyaluronic acid (HA), 16–17  
 Hydrogel tubes, 64  
 Hydrogels, 60, 76  
   applications, 76, 105–122  
   chemotherapeutic agents delivery using, 121  
   classification, 77  
   complexing, 91, 115–117  
   drug delivery applications, 121  
   environmentally responsive, 88–91  
   glucose-sensitive systems, 117–119

macroporous, 82  
 microporous, 82  
 network structure, 77–83  
 neutral, 105–110  
 nonporous, 82  
 pH-sensitive, 89–90, 110–112, 114–115  
 poly(glyceryl methacrylate)  
   p(GMA)–collagen, 63  
 protein-based, 120  
 solute permeability properties, 77  
 solute transport in, 83–87  
 swollen temperature, 89  
 synthetic, 63  
 temperature-sensitive, 90–91, 112–115  
 Hydrogen-bonding complexes, 92  
 Hydrogen bonds, 97–98  
   inter-associating, 97  
   self-associating, 97  
 Hydrophilic polymer networks, 76  
 Hydrophilicity/hydrophobicity, 30, 76, 104  
 Hydrophobic monomers, 100  
 Hydrophobicity/hydrophobicity, 30, 76, 104  
 2-Hydroxyethyl methacrylate (HEMA), 96, 99  
 Hydroxypropyl cellulose (HPC), 113

## I

ICAM-1, 11  
 ICAMs, 16  
 Ideal surfaces, 34–35  
 Immunoglobulins, 9, 16–17  
 Inert biomaterials, 1–2  
 Inflammatory response, 102  
 Infrared spectroscopy, 96–97  
   and polymer complexation, 97–98  
 Inside-out signaling, 12–13  
 Insulin delivery systems, 119–120  
 Insulin-like growth factor (IGF), 159  
 Integrin–ligand binding, 18–25  
 Integrin–ligand interactions, 12  
 Integrins, 9–13, 17, 19, 36–39  
 Intracellular domain, 9

## K

Ketene, polymerization with, 176  
 KRSR, 38

**L**

L-selectin, 15  
 Lactose, 15  
 Laminin, 16, 48, 50, 55, 58, 60  
 Lectin-carbohydrate interactions, 40  
 Lectins, 15, 40  
 Leukocyte adhesion, 28  
 Leukocyte binding, 40  
 Lower critical solution temperature (LCST), 91, 112-114

**M**

Macrophages, 103  
 Matrix-based systems, solute transport in, 87  
 Medical devices, 2  
 Melt polycondensation, 174-175  
 Membrane proteins, 13  
 Methacrylic acid (MAA), 96  
 Methyl methacrylate, 100  
 Mitogen-activated protein kinases (MAPK), 21  
 Molecular design, 75  
 Monocyte activation, 3  
 Monosaccharide asialoglycoprotein ligands, 40  
 Monosaccharides, 15  
 Mucosal delivery, aerosols and systems designed for, 212-213  
 Multigrooved substrates, 32

**N**

*N*-acetyllactosamine, 40  
*N*-methyl pyrrolidinone (NMP), 98  
 Naked plasmid DNA (pDNA), 142  
   limitations, 134-135  
 NCAM, 16  
 Neomembranes, 56  
 Nerve growth factor (NGF), 48, 51, 64-65  
   silicone tubes prefilled with, 59  
 Nerve growth factor (NGF)-treated nitrocellulose implants, 60  
 Nerve guide conduit, 58  
 Nerve regeneration, polymeric biomaterials for, 47-74

Neural glial cell adhesion molecule (NgCAM), 16  
 Neural stem cells, 61  
 Neurotrophic factors, 64, 66  
 Neurotrophin-3 (NT-3), 64  
 Neutral networks, tissue engineering, 98-105  
 Nitrocellulose implants, 60  
 Nonviral gene therapy, 136  
   biomaterials for, 136-141  
 Nonviral plasmid DNA, 160  
 Nucleic acids, 131-132

**O**

Office of Combination Products, 2  
 Oligosaccharides, 14  
 Osteoblasts, 33  
 Osteopontin, 16  
 Outside-in signaling, 13, 20

**P**

*p*-nitroaniline (PNA), 191, 195  
   encapsulation, 154  
 P-selectin, 15, 40-41  
 PAA, 93, 111, 118, 175, 192-193  
 PAA/PEG complexes, 93-94  
 Parkinson's disease, 64, 66  
 PBA, 118  
 PCDA, 177  
 PCPA, 179, 191, 200  
 PCPAM, 187  
 PCPH, 174, 179, 191, 193-194, 200  
 P(CPH-CPS), 186  
 PCPM, 173, 179, 193, 200  
 PCPO, 179, 191, 200  
 PCPP, 174-175, 179, 191-194, 199-200  
 P(CPP-DDA), 174  
 P(CPP-SA), 174  
 PCPS, 186, 200  
 PCPSM, 187  
 PCPV, 179, 191, 200  
 PDDA, 174-175, 177, 191-194, 200, 205  
 PDEAEMA, 110  
 P(DEAEMA-co-HEMA), 111  
 PDLA, 56-58  
 PDLLA, 62  
 PDMAEMA, 110, 118

- P(DMAEMA-*co*-HEMA), 111  
 pDNA *see* Plasmid DNA  
 PDX, 177  
 PEG, 34–35, 38, 95, 105, 109–110, 115,  
     119–120, 139, 152, 156  
 PEG 400, 66  
 PEG chain length, 92–96  
 PEG-dimethacrylates, 110  
 PEG-monomethacrylates, 110  
 PEG-PLA, 151–152  
 PEI, 139  
 PEI/DNA complexes, 139–140  
 PELA, 62  
 PEO, 2, 105, 109–110, 112, 121  
 Peptide-modified surfaces, 36–37  
 Peripheral nerve damage, 47  
 Peripheral nervous system, polymers for  
     regeneration, 48–60  
 PEVAc, 105, 161  
 PFA, 177, 192, 194  
 PFAD, 178, 193  
 PFG-NMR technique, 95  
 PGA, 59  
 pH effect on polymer mesh size, 116  
 pH-sensitive hydrogels, 89–90, 110–112  
 Phagocytosis, 102  
 Pharmacotectonics concept, 66  
 PHB, 54, 64  
 PHEMA, 34, 63–64, 77, 97–101, 104–106,  
     115, 118–119  
 PHEMA-*co*-AA, 111  
 PHEMA-*co*-MAA, 111  
 p(HEMA-*co*-MMA), 64  
 PHFB, 189  
 PHMCSA, 188  
 Photolithographic methods, 22  
 PHPMA, 63, 139  
 PHSRN, 37  
 PIPA, 179, 191–192, 194  
 P(IPA-SA), 174  
 PLA, 121, 211  
 PLA/PLGA, 144  
 Plasmid DNA, 133, 136, 138, 141, 157–158,  
     161–162  
     encapsulation, 143–150, 152, 154  
     entrapment and release, 157  
     interaction with cationic lipids, 137  
     nonviral, 160  
 PLC, 54, 59–60  
 PLCA, 189  
 PLGA, 53, 55, 57, 65–66, 142–157, 161  
 PLGA-CTAB microspheres, 153  
 PLGA-CTAB nanospheres, 153  
 PLL, 139, 147–148  
 PLLA, 53, 56–57, 59  
 PMAA, 93, 110, 115–117, 122  
 PMAA hydrogels, 95  
 P(MAA-*g*-EG), 118–119  
 PMAA/PEG complexes, 93–94  
 PNA, 198  
 PNIPAAm, 112–113, 115, 118  
 PNVP, 105  
 Polylactic acid, 57  
 Polyacrylamide, 34  
 Polyacrylamide (PAAm), 110  
 Poly(acrylic acid) (PAA), 110  
 Poly(adipic acid) (PAA), 177  
 Poly(alpha-hydroxy acid), 61  
 Poly(amidoamine) dendrimers, 139  
 Poly(amidoamine) (PAMAM)  
     dendrimers, 140  
 Polyanhydride carriers for controlled  
     release, 209–213  
 Polyanhydride discs for treatment of  
     glioblastoma multiforma, 210  
 Poly(anhydride-*co*-alkylene carbonate)s, 188  
 Poly(anhydride-*co*-amide)s, 187–188  
 Poly(anhydride-*co*-ester)s, 183–187  
 Poly(anhydride-*co*-ether)s, 183–187  
 Poly(anhydride-*co*-imide)s, 183  
 Poly(anhydride-*co*-urethane)s, 189  
 Polyanhydrides  
     additional chemistries, 188–189  
     aliphatic, 193  
     amorphous phase behavior, 195–199  
     aromatic, 179–182, 194  
     as surface erodible biomaterials, 171  
     biocompatibility, 199–200  
     branched, 188  
     characterization, 189–200  
     chemical changes during erosion, 206  
     chemical characterization, 189–192  
     chemistry and synthesis, 172–189  
     crystalline morphology, 193–195  
     crystallinity, 196–197  
     degradation kinetics, 200–208  
     discretized models, 209  
     drug release kinetics, 201, 207–209  
     drug release rates, 201–205  
     early synthesis, 172–173

- erosion, 201, 207–209
  - erosion number, 208
  - erosion rate constants, 202–203
  - experiments, 200–206
  - from unsaturated and fatty acid-derived monomers, 177–179
  - FTIR, 189–191
  - future opportunities, 213–214
  - <sup>1</sup>H NMR, 189–191
  - implantable systems, 210
  - in vitro* degradation, 201
  - injectable systems, 211–212
  - laminated devices for pulsatile release, 210
  - microstructure, 195–199
  - model formulations testing *in vitro* and *in vivo*, 209
  - modeling, 207–209
  - modulating erosion rates, 201–205
  - phenomenological models, 208–209
  - solubility, 191–192
  - surface changes during erosion, 205–206
  - synthesis for drug delivery, 173–176
  - thermal properties, 196–197
  - thermal transitions, 192–193
  - Poly[ $\alpha, \omega$ (*p*-carboxyphenoxy)alkanes], 173
  - Poly(azelaic acid) (PAZ), 200
  - Poly(bis(hydroxyethyl)terephthalate-ethyl ortho-phosphate/terephthaloyl chloride), 58
  - Polydimethylsiloxane, 48
  - Polyelectrolyte complexes, 92
  - Polyesters, 169
  - Polyethers, 169
  - Poly(glycerol methacrylate) p(GMA)–collagen hydrogels, 63
  - Poly(glycolic acid), 50
  - Poly(lactic acid) (PLA), 50, 186, 195
  - Poly(lactide-*co*-glycolic acid), 57
  - Poly(lactide-*co*-glycolide), 65–66
  - Poly(lithocholic acid), 189
  - Polymer-based particles for controlled DNA release, 141–157
  - Polymer complexation and infrared spectroscopy, 97–98
  - Polymeric biomaterials for nerve regeneration, 47–74
  - Poly(phosphoester) conduits, 57
  - Poly(vinylidene fluoride), 51
  - Porogens, 101
  - Porous materials, tissue response to, 102–103
  - PPA, 200
  - PPDP, 174, 179, 191
  - Protein adsorption, 26–28, 34, 39
  - Protein-based hydrogels, 120
  - Protein conformation, 26–27
  - Protein delivery
    - and gene therapy, 132–133
    - limitations, 132–133
  - Protein diffusion coefficient, 27
  - Protein diffusivity, 27
  - Protein–surface interactions, 28
  - Proteoglycans, 13–15, 39–41
  - PSA, 175, 177–178, 191–195, 198, 200–201, 204–205
    - FTIR spectrum, 189
  - P(SA-*alt*-TA), 179
  - PSA–fatty acid-based copolymers, 179
  - PTA, 173, 175, 179, 191–192, 194, 199
  - PTFE, 104
  - PTMCSA, 188
  - PTPA, 179
  - PVA, 34, 103–105, 107–109, 111, 118, 145, 148, 152, 161
  - PVP, 145, 152
  - PXDA, 179
- R**
- Receptor affinity, 11
  - Receptor binding to ligands, 10
  - Receptor diffusivity, 10
  - Receptor–ligand binding, 9
  - REDV (Arginine–Glutamine–Aspartic acid–Valine), 11, 38
  - Responsive networks, 110–119
  - RGD (Arginine–Glycine–Aspartic acid), 11, 37–38, 63, 104
  - Ricinoleic acid, 179
  - Ricinoleic half-esters, 179
  - Ring opening polymerization, 176
  - Rubber elasticity theory, 81–82
- S**
- Saccharides, 14
  - Salicylic acid, 210

## Scaffolds

- biodegradable polymer, 61
- DNA release from, 161–162
- for controlled DNA delivery, 157–162
- tissue engineering, 162
- Schwann cells, 48, 50, 52, 58, 61
- Secreted protein acidic and rich in cysteine (SPARC), 17
- Selectins, 9, 13–15, 39–41
- Severe combined immunodeficiency (SCID), 131
- Sialyl-Lewis<sup>x</sup> (sLe<sup>x</sup>), 41
- Signal transduction, 18–25
- Silicone, 60
- Silicone chambers, 49–50
- Silicone conduits, comparative studies, 59
- Silicone rubber, 48
- Silicone tubes, 50
  - electrical circuit within, 61
  - prefilled with NGF, 59
- Small-angle X-ray scattering (SAXS), 194
- Sodium chloride, 66
- Solute transport
  - in hydrogels, 83–87
  - in matrix-based systems, 87
- Specificity, 5
- Spinal cord injuries, 47
- Spinal cord regeneration, 61–62
- Spinal cord tissue, 60–61
- Spray-drying technique, 149–150
- Star polymers, 121
- Stereocomplexes, 92
- Styrene, 119
- Surface chemistry, 28–30
- Surface-erodible biomaterials for drug delivery, 169–218
- Surface erosion, 172
- Surface plasmon resonance (SPR), 195
- Surface receptors, 11, 24
- Surface topography, 31–33
- Syndecans, 17

## T

- Teflon, 60
- Tenascins, 17
- Tetrahydrofuran (THF), 191–192
- Three-dimensional polymeric networks
  - as biomaterials, 76–105
  - structural characteristics, 82–83

## Thrombogenicity, 3

- Thrombospondins (TSPs), 17
- Tissue attachment, chemical and physical determinants, 103–105
- Tissue culture polystyrene (TCPS) vs. laminin-coated surfaces, 8
- Tissue engineering
  - neutral networks, 98–105
  - scaffolds, 162
- Tissue–implant interactions, 101–105
- Tissue regeneration, 162
- Tissue response to porous materials, 102–103
- Transforming growth factor  $\beta$  (TGF- $\beta$ ), 159
- Transmembranous domain, 9
- Trifluoroethanol (TFE), 151
- Trophic factors, 48, 50
- Tyrosine-phosphorylated proteins, 20

## U

- Ulex europaeus I (UEA I), 40
- Unsintered hydroxyapatite/poly-L-lactide (u-HA/PLLA), 62

## V

- Vaccination applications, DNA release in, 153–157
- VCAMs, 16
- Viral gene therapy, 135
- VP/AAM matrix, 95

## W

- Weibel-Palade bodies, 15
- Wide-angle X-ray diffraction (WAXD), 195, 198
- Wound healing, 158–159

## X

- X-ray diffraction (XRD), 194

## Y

- YISGR, 104